During the prestigious virtual congress of the European Society of Cardiology (ESC), researchers from the Montreal Heart Institute (MHI) presented recent data regarding the impact of colchicine on cardiovascular disease.

These three new analyses from the COLCOT (COLchicine Cardiovascular Outcomes Trial) clinical trial confirm the benefits of colchicine, an inexpensive and already available drug, to prevent cardiovascular events in patients who survived a heart attack, also known as myocardial infarction (MI).

INSTRUCTIONS FOR VISITORS OF HOSPITALIZED PATIENTS (click here to print the instructions).  

You must indicate your presence as soon as you arrive at the nursing unit before you go to a room. 

When you arrive at the Institute, you must also:

Colchicine, a common drug to treat gout, is being evaluated as a potential treatment in the fight against coronavirus